Tan Tina, Trindade Evelinda, Skowronski Danuta
Feinberg School of Medicine, Division of Infectious Disease, Children's Memorial Hospital, 2300 Children's Plaza, Box 20, Chicago, IL 60614-3394, USA.
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S10-8. doi: 10.1097/01.inf.0000160708.43944.99.
The World Health Organization recommended that a pertussis incidence of <1 case per 100,000 population be achieved in Europe by 2000. Available data indicate that this goal has generally not been achieved, and the incidence is actually rising in some countries. Understanding the reasons for this increased incidence may lead to better global control of pertussis. In the majority of countries where pertussis is a notifiable disease, a case-based national surveillance system is in place. However, different case definitions, methods of diagnosis and reporting and surveillance systems make direct intercountry comparisons difficult, and pertussis is not a statutory notifiable disease in every country. Nevertheless the general consensus is that reported incidences are probably considerably lower than the actual incidence of pertussis; underreporting is common. Prolonged cough may be the only clinical feature in adolescents or adults, who may present for diagnosis late (precluding laboratory confirmation) or not at all. When they do present, their condition is often misdiagnosed because, in part, clinicians continue to perceive pertussis as a childhood disease. Despite underreporting, an increased incidence of infant, adolescent and adult pertussis has been observed worldwide since the introduction of widespread vaccination. This is of concern because adolescents and adults have been identified as a source of transmission of pertussis to very young infants who are unimmunized or partially immunized and thus more vulnerable to disease-related complications and higher mortality. In recent years, acellular pertussis vaccines have been incorporated into the immunization schedules of many developed countries, gradually replacing whole cell vaccines. Dosing schedules vary between countries, although primary immunization with 3 doses of the pertussis vaccine within the first 6 months of life exists in most countries. Only Australia, Austria, Canada, France and Germany have incorporated an adolescent booster dose into their current immunization schedules, in recognition of the rising incidence of pertussis in adolescents and adults. Despite high coverage rates for primary immunization in infants and children, pertussis continues to be a global concern, with increased incidence widely noted. This global epidemiologic summary highlights differences worldwide in pertussis reporting, incidence and approaches to prevention. It underscores a general shift in the age distribution of pertussis toward older groups. Understanding the link between these observations may lead to better informed global control strategies, especially those pertaining to immunization schedules and use of pertussis vaccine.
世界卫生组织建议,到2000年欧洲百日咳发病率应达到每10万人中少于1例。现有数据表明,这一目标总体上尚未实现,而且在一些国家发病率实际上还在上升。了解发病率上升的原因可能有助于更好地在全球范围内控制百日咳。在大多数将百日咳列为须上报疾病的国家,都建立了基于病例的国家监测系统。然而,不同的病例定义、诊断和报告方法以及监测系统使得各国之间难以进行直接比较,而且百日咳在每个国家并非都是法定须上报疾病。尽管如此,普遍的共识是,报告的发病率可能远低于百日咳的实际发病率;漏报情况很常见。持续性咳嗽可能是青少年或成年人唯一的临床特征,他们可能很晚才就医诊断(无法进行实验室确诊),甚至根本不就医。当他们就医时,病情往往被误诊,部分原因是临床医生仍然认为百日咳是一种儿童疾病。尽管存在漏报情况,但自广泛接种疫苗以来,全球范围内婴儿、青少年和成人百日咳的发病率都有所上升。这令人担忧,因为青少年和成人已被确定为百日咳传播给未接种疫苗或部分接种疫苗的非常年幼婴儿的传染源,这些婴儿更容易出现与疾病相关的并发症和更高的死亡率。近年来,无细胞百日咳疫苗已被纳入许多发达国家的免疫规划,逐渐取代了全细胞疫苗。各国的接种程序各不相同,不过大多数国家在婴儿出生后的头6个月内都进行3剂百日咳疫苗的基础免疫。只有澳大利亚、奥地利、加拿大、法国和德国在其现行免疫规划中纳入了青少年加强剂量,以应对青少年和成人百日咳发病率的上升。尽管婴儿和儿童基础免疫的覆盖率很高,但百日咳仍然是一个全球关注的问题,发病率上升的情况广泛存在。这一全球流行病学综述突出了世界各地在百日咳报告、发病率和预防方法上的差异。它强调了百日咳年龄分布总体上向年龄较大群体的转变。了解这些观察结果之间的联系可能有助于制定更明智的全球控制策略,特别是那些与免疫规划和百日咳疫苗使用有关的策略。